10 assets in Hereditary Disease

Therapeutic assets addressing Hereditary Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Aoc 1044 Hereditary Disease	Avidity Biosciences, Inc.	P3	B (60)
Nexiguran Ziclumeran Hereditary Disease	Intellia Therapeutics	P3	B (60)
Zeleciment Rostudirsen Hereditary Disease	Dyne Therapeutics	P3	B (60)
Alpelisib Hereditary Disease	Borstkanker Onderzoek Groep	P2	CCC (53)
Fulvestrant Hereditary Disease	Borstkanker Onderzoek Groep	P2	CCC (53)
Thalidomide Hereditary Disease	National Institute of Blood and Marrow Transplant (NIBMT), Pakistan	P2	CCC (53)
Nl-Scn2A-002 Hereditary Disease	University of California, San Diego	P1/2	CCC (48)
Fluoxetine Hereditary Disease	Holland Bloorview Kids Rehabilitation Hospital	N/A	D (30)
4-phenylbutyrate Hereditary Disease	Children's Hospital of Fudan University	P2/3	NR ()